SCHEMBL5136197

SCHEMBL5136197

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(OC(F)(F)F)cc1)CC1CCCCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.40
CRHR1 P34998 3/20 0.36
TRPM8 Q7Z2W7 2/20 0.36
AVPR1B P47901 1/20 0.35
DRD2 P14416 1/20 0.35
DRD3 P35462 1/20 0.35
CCR5 P51681 2/20 0.34
DHFR P00374 2/20 0.34
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.34
DDHD2 O94830 1/20 0.34
CCR4 P51679 1/20 0.34
TSHR P16473 2/20 0.33
UBE2M P61081 1/20 0.33
DCUN1D1 Q96GG9 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP3A4 P08684 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135374 0.91 C5AR1 (0.40) C5AR1CRHR1CCR4
SCHEMBL5134723 0.90 C5AR1 (0.42) C5AR1CRHR1CCR4TSHRKDM4E
SCHEMBL5137557 0.90 C5AR1 (0.42) C5AR1DRD2DRD3TSHRKDM4E
SCHEMBL5137594 0.90 C5AR1 (0.42) C5AR1DRD2DRD3
SCHEMBL5136823 0.90 C5AR1 (0.42) C5AR1DRD2DRD3CCR5TSHR
SCHEMBL5134999 0.90 C5AR1 (0.44) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL647827 0.89 C5AR1 (0.41) C5AR1DRD2DRD3TSHRKDM4E
SCHEMBL5135713 0.89 C5AR1 (0.44) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL5137864 0.89 C5AR1 (0.44) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL650100 0.89 C5AR1 (0.40) C5AR1CRHR1DRD2DRD3CCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed